News
Vamousse® head lice treatment now distributed by CVS in the USA
25 March 2015
TyraTech, Inc. (AIM: TYR and TYRU), a life sciences company focused on nature-derived insect and parasite control products, is pleased to announce that it has secured listings for its Vamousse Treatment product with the CVS Pharmacy Group in the USA.
CVS Pharmacy
CVS Pharmacy is the second largest pharmacy chain after Walgreens in the United States, with more than 7,600 stores and 100 million American customers each year. This listing, which follows the recent announcement of deals with the top three pharmaceutical distributors in the USA, represents a further key milestone for the roll-out of TyraTech's Vamousse products in America. It is expected that the Treatment product will be available in the majority of CVS stores nationwide in the USA from the end of April 2015.
Tesco update
In addition to the progress in the USA, we are pleased to announce positive developments in our UK distribution network also. Tesco, which had until recently been selling the Vamousse Treatment product through its pharmacy counters, will also place the product into open shelving, making it more accessible and visible to customers. Tesco has also confirmed separately, that it will almost double the number of stores stocking TyraTech's Vamousse Treatment product.
Bruno Jactel, Chief Executive Officer, said: "The CVS listing is probably our most important milestone this year as it firmly establishes our product in the pharmacy segment in the USA and significantly enhances the profile of our brand. I would like to thank our partner, the Greenwood Group, which has been instrumental in establishing the commercial relationship with CVS and our retail partners in the USA. Together with the recent announcement of the three biggest pharmaceutical distributors in the USA, and Lloyds and Day Lewis in the UK, we are very excited by the growth opportunities presented by the continually expanding distribution network for Vamousse products."
Further information on Vamousse® is available on the Company's website at http://www.vamousselice.com/
For further information please contact:
| TyraTech Inc. Bruno Jactel, Chief Executive Officer Vincent Morgus, Chief Financial Officer and Treasurer |
Tel: +1 919 415 4340 Tel: +1 919 415 4287 |
| SPARK Advisory Partners Limited, Nominated Adviser Matt Davis / Mark Brady |
Tel: +44 203 368 3551 Tel: +44 203 368 3552 |
| Allenby Capital Limited , Joint Broker Chris Crawford |
Tel: +44 20 3328 5656 |
| Whitman Howard Limited, Joint Broker Ranald McGregor-Smith/ Niall Devins |
Tel: +44 20 7659 1240 |
| Walbrook, Financial PR and IR Nick Rome/ Guy McDougall |
Tel: +44 20 7933 8790 |
Disclaimer for U.S. Site Visitors
This web site contains investor-related information which is restricted to non-U.S. persons or Qualified Institutional Buyers as defined in Rule 144A of the U.S. Securities Act of 1933, as amended (the "Securities Act"). The information provided herein is not an offer to buy or sell, or a solicitation of an offer to buy or sell, any TyraTech, Inc. securities. By viewing pages on this web site, you agree and acknowledge that TyraTech, Inc.'s common stock has not been registered under the Securities Act and that you are a non-U.S. person, Qualified Institutional Buyer as defined in Rule 144A of the Securities Act., or you are not holding, acquiring or selling TyraTech, Inc. common stock for the account or benefit of any U.S. person.